Receptor for Hepatitis B and D Virus.
- Author:
Kyun Hwan KIM
1
Author Information
- Publication Type:Review
- Keywords: Hepatitis B virus; Receptor; Sodium taurocholate cotransporting polypeptide
- MeSH: Bile Acids and Salts; Hepatitis B virus; Hepatitis B*; Hepatitis B, Chronic; Hepatitis Delta Virus; Hepatocytes; Humans; Mortality; RNA-Directed DNA Polymerase; Taurocholic Acid; Tupaiidae
- From:Korean Journal of Medicine 2015;89(1):35-42
- CountryRepublic of Korea
- Language:Korean
- Abstract: Chronic hepatitis B affects 400 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. All clinically available hepatitis B virus (HBV) drugs are nucleoside or nucleotide analogs that inhibit viral reverse transcriptase (RT) activity. Resistance to these HBV drugs has been widely reported, and is due to specific mutations in the viral RT domain. Therefore, the development of new, non-polymerase targeting anti-HBV agents is urgently needed. A potential drug target, the HBV receptor that mediates the viral entry process, has been recently identified using human primary hepatocytes, northern tree shrew (Tupaia belangeri) hepatocytes, and HepaRG cells. A transporter of bile acids, sodium taurocholate cotransporting polypeptide (NTCP), was identified as the receptor for HBV and hepatitis D virus, and the transport function of NTCP was correlated with HBV entry. Therefore, functional inhibitors of NTCP may inhibit HBV infection, and viral entry was blocked by several NTCP receptor-targeting compounds. The HBV receptor is an attractive target for development of entry inhibitors, and serves as a model for the mechanistic study of HBV entry and infection. This review will summarize the characteristics and clinical importance of NTCP, and will discuss the potential therapeutic use of NTCP inhibitors to prevent HBV entry.
